首页> 美国卫生研究院文献>Acta Crystallographica Section E: Crystallographic Communications >One-pot synthesis of (1RS21SR)-diethyl 2-23-amino-22-eth­oxy­carbonyl-81114-trioxa-25-aza­tetra­cyclo­19.3.1.027.01520penta­cosa-24615(20)161822-heptaen-25-ylbut-2-endioate
【2h】

One-pot synthesis of (1RS21SR)-diethyl 2-23-amino-22-eth­oxy­carbonyl-81114-trioxa-25-aza­tetra­cyclo­19.3.1.027.01520penta­cosa-24615(20)161822-heptaen-25-ylbut-2-endioate

机译:一锅合成(1RS21SR)-二乙基2- 23-氨基-22-乙氧基羰基-81114-三恶唑-25-氮杂四环19.3.1.027.01520 pentacosa-246 15(20)161822-庚烯-25-基 but-2-endioate

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The title compound, C30H34N2O9 (>4), is a product of the Michael reaction of aza­crown ether with dimethyl acetyl­enedi­carboxyl­ate modified by an addition of NH3 (aq.) at 298 K. The aza-14-crown-4-ether ring adopts a bowl conformation. The dihedral angle between the planes of the benzene rings fused to the aza-14-crown-4-ether moiety is 8.65 (5)°. The tetra­hydro­pyridine ring has a boat conformation. The mol­ecular conformation is supported by one N—H⋯O and two C—H⋯O intra­molecular hydrogen bonds. Both heterocyclic and amino N atoms have essentially planar configurations (sums of the bond angles are 359.35 and 358.00°). Compound >4 crystallizes as a racemate consisting of enanti­omeric pairs of the 1R,21S diastereomer. In the crystal, mol­ecules of >4 are connected by N—H⋯O hydrogen bonds, forming chains along [100]. According to the PASS program (computer prediction of biological activities), compound >4 may exhibit anti­allergic (72% probability) and anti­asthmatic (67%) activity, as well as be a membrane permeability inhibitor (65%).
机译:标题化合物C30H34N2O9(> 4 )是氮杂皇冠醚与在298°K下添加NH3(水溶液)改性的乙炔二羧酸二甲酯的迈克尔反应产物。 4-醚环采用碗状。稠合至氮杂14-冠-4-醚部分的苯环平面之间的二面角为8.65°(5)°。四氢吡啶环具有舟状构象。分子构象由一个NHOH和两个CHOH分子内氢键支撑。杂环和氨基N原子均具有基本上平面的构型(键角之和为359.35和358.00°)。化合物> 4 结晶为外消旋体,由1R,21S非对映异构体的对映体对组成。在晶体中,> 4 分子通过N-H⋯O氢键连接,沿着[100]形成链。根据PASS程序(计算机预测生物活性),化合物> 4 可能具有抗过敏(72%概率)和抗哮喘(67%)活性,并且是一种膜通透性抑制剂(65%) 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号